NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer
Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.
Category
  • Bladder Cancer
  • Genitourinary Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Emerging Therapies in the Treatment of Bladder Cancer
A number of new treatment options for different stages of bladder cancer are currently under investigation, which will make education important to cover the data behind these therapies and how they might be incorporated into future clinical practice. Of interest, treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer are currently being evaluated in clinical trials as well as new systemic therapy options for muscle-invasive and metastatic disease.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation